Kriya ac­quires gene ther­a­py start­up for undis­closed sum; Com­pu­gen wins mile­stone pay­ment from As­traZeneca

Shankar Ra­maswamy’s Kriya Ther­a­peu­tics se­cured a buy­out for an un­known amount Wednes­day morn­ing.

Kriya ac­quired pri­vate­ly held Red­pin Ther­a­peu­tics, which is de­vel­op­ing gene ther­a­pies for the ner­vous sys­tem, the com­pa­nies an­nounced. Ac­cord­ing to a press re­lease, the buy­out serves as a “foun­da­tion” for Kriya’s neu­rol­o­gy port­fo­lio. The pair did not say how much it took to buy Red­pin.

“Red­pin’s in­no­v­a­tive chemo­ge­net­ics plat­form has the po­ten­tial to trans­form the lives of pa­tients suf­fer­ing from in­tractable neu­ro­log­i­cal con­di­tions,” Ra­maswamy, Kriya’s CEO, said in the re­lease. “We are look­ing for­ward to in­te­grat­ing Red­pin’s plat­form and pipeline in­to Kriya’s gene ther­a­py en­gine.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.